Article
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Feb 2020
Cho Jang Ho, Lim Sung Hee, An Ho Jung, Kim Ki Hwan, Park Keon Uk, Kang Eun Joo, Choi Yoon Hee, Ahn Mi Sun, Lee Myung Hee, Sun Jong-Mu, Lee Se-Hoon, Ahn Jin Seok, Park Keunchil, Ahn Myung-Ju
Abstract excerpt
PURPOSE: Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations. PATIENT AND METHODS: This was a multicenter, single-arm, open-label, phase II study in Korea. Patients with histologically confirmed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.